Breast Cancer: Major Accomplishments
The diversity of the Perlmutter Cancer Center's investigators promotes a strong, balanced multidisciplinary approach to the investigation of breast cancer and mammary biology. The Breast Cancer Research Program has been highly successful in obtaining significant extramural research funding to support its major scientific objectives in basic, translational, and clinical research endeavors.
Locally Advanced Breast Cancer (LABC)
- Center of Excellence (COE) grant for LABC ($5.7 million, DOD BCRP), supporting "Response, Resistance and Metastasis of Locally Advanced Breast Cancer," a six-year clinical, translational, and basic research program.
- Clinical-Translational Research Program grant from the Breast Cancer Research Foundation (BCRF). This program was originally funded by the BCRF for four years for a project entitled "Genetic and Molecular Markers for Targeted Treatment of LABC in New York Women." It has been renewed for funding for another four years for a project that builds on our previous success toward a more focused goal: translating the Akt/mTOR pathway to treatment of LABC.
Angiogenesis in Breast Cancer and Anti-angiogenesis Therapy
Clinical-Translational Research Program, Development of anti-angiogenic PTC299, a specific inhibitor of VEGF mRNA translation, a 3 year clinical-translational research program
Hormonal Signaling in Breast Cancer
Clinical-Translational Research Program: breast cancer chemoprevention by SOM230, an IGF-1 action inhibitor; a two-year investigation of antiestrogenic inhibition of IGF-1 in the high risk population.
Socio-Cultural and Inreach/Outreach Program
Integrated Breast Cancer Care for Medically Underserved Multiethnic Women in New York (Avon Research Foundation): a multi-ethnic "outreach/inreach" program to develop new approaches for increased access to and sustained participation in clinical trials for minority and medically underserved women with breast cancer.
Radiobiology and Immunity Research
Several National Institutes of Health, Department of Defense, and other grants to support efforts aimed at understanding the mechanism of action of radiation as an adjuvant for cancer immunotherapy, and its effects on the extracellular matrix related to fibrosis in breast cancer.